![]() ![]() Benchmark was also the founding alliance partner of hyperCORE International, a network of premier sites, and VaxCorps, a network of clinical research centers specializing in vaccine trials. During the development of the initial COVID-19 vaccines, Benchmark emerged as the preferred SMO due to its longstanding reputation for quality among pharma sponsors and served as a model of excellence across the industry. With the global vaccine market expected to exceed $65 billion by 2026, CROs are expanding their vaccine expertise in order to serve the growing demand.įounded in 1997, Benchmark Research (Benchmark) has distinguished itself the leading site network for vaccine trials in the industry, having conducted more than 1,000 trials with 40,000+ participants across its network of 10 clinical trial sites. These sites provide end-to-end support services, handling everything from patient recruitment to regulatory compliance to data collection in timelines that are more compressed than traditional clinical trials. To bring vaccines to market successfully, sponsors rely on sites with specific vaccine expertise to conduct clinical trials. SRPT YTD mountain Sarepta stock has slipped more than 17% so far in 2023.Benchmark Research has been acquired by IQVIA, combined with Avacare, to expand vaccine and clinical trial site capabilities. ![]() Of the 14 analysts covering the stock, 71% rate it a buy, while the average analyst price target implies upside of nearly 64%. Food and Drug Administration for a gene therapy for Duchenne muscular dystrophy in boys ages 4 to 5. While the stock has slipped more than 17% this year, the company recently received approval from the U.S. Earlier this month, Canaccord Genuity initiated the stock with a buy rating, noting: "We believe autonomous vehicles (AVs) are set to increase resource utilization, improve productivity, save lives, and much more." MBLY YTD mountain Mobileye stock has added roughly 4% since January. Three-quarters of analysts covering the stock rate it a buy, and the average price target indicates 30% upside over the next 12 months. Mobileye Global, a company that helps develop technology, software and cameras for autonomous driving, is also expected to drive the Nasdaq going forward. MELI YTD mountain Shares have soared more than 38% so far this year. Nearly 73% of analysts that cover MercadoLibre rate the stock as a buy, with their average price target implying about 38% upside to current levels, FactSet data shows. The stock has gained more than 38% year to date. Latin American online marketplace MercadoLibre also made the cut. FANG YTD mountain Diamondback Energy stock has slipped more than 6% from January. Their average price target implies about 34% upside compared with current levels. However, 76.7% of the 27 analysts polled that cover it rate the stock as a buy. Texas-based oil and natural gas firm Diamondback Energy made the list. Market capitalization of $5 billion or more. At least 65% of analysts maintain buy ratings. Against this backdrop, CNBC Pro screened the Nasdaq Composite to find which stocks can help the index keep its momentum going, abiding by the following criteria: Average analyst price targets imply at least 30% upside. Other winners include Ambrx Biopharma and Cipher Mining, with gains of more than 600% and 412%, respectively. Shares of Apple, Google parent Alphabet, Meta Platforms and Nvidia have soared in 2023. Excitement around artificial intelligence propelled the benchmark after a tough 2022. That year, the Nasdaq rallied 37.1% in the first half and finished 1983 up nearly 20%. The tech-heavy index has soared nearly 29% this year and is currently on pace for its best first half since 1983. The Nasdaq Composite has been on fire so far in 2023. Personal Loans for 670 Credit Score or Lower Personal Loans for 580 Credit Score or Lower ![]() Best Debt Consolidation Loans for Bad Credit ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |